Cargando…

Effectiveness of adjuvant trastuzumab in daily clinical practice

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40–50% and reduces the risk of dying from HER2 positive breast cancer by one th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matos, Erika, Zakotnik, Branko, Kuhar, Cvetka Grasic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Versita, Warsaw 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230562/ https://www.ncbi.nlm.nih.gov/pubmed/25435855 http://dx.doi.org/10.2478/raon-2013-0081

Ejemplares similares

Digital ischemic events related to gemcitabine: Report of two cases and a systematic review
por: Kuhar, Cvetka Grasic, et al.
Publicado: (2010)

A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients
por: Matos, Erika, et al.
Publicado: (2016)

Human epidermal growth factor receptor 2-positive microinvasive breast carcinoma with a highly aggressive course: a case report
por: Grasic Kuhar, Cvetka, et al.
Publicado: (2014)

Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer
por: Kuhar, Cvetka Grašič, et al.
Publicado: (2023)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

The Biology and Clinical Potential of Circulating Tumor Cells
por: Lozar, Taja, et al.
Publicado: (2019)

Changes in the quality of life of early breast cancer patients and comparison with the normative Slovenian population
por: Grasic Kuhar, Cvetka, et al.
Publicado: (2023)

Graves disease and metastatic hormonal-active Hürthle cell thyroid cancer: A case report
por: Besic, Nikola, et al.
Publicado: (2021)

Neuroendocrine Carcinoma of the Larynx and Pharynx: A Clinical and Histopathological Study
por: Strojan, Primož, et al.
Publicado: (2021)

Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer
por: Marinko, Tanja, et al.
Publicado: (2018)

Mobile App for Symptom Management and Associated Quality of Life During Systemic Treatment in Early Stage Breast Cancer: Nonrandomized Controlled Prospective Cohort Study
por: Grašič Kuhar, Cvetka, et al.
Publicado: (2020)

Morphological Features of Breast Cancer Circulating Tumor Cells in Blood After Physical and Biological Type of Isolation
por: Jesenko, Tanja, et al.
Publicado: (2021)

The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma
por: Miceska, Simona, et al.
Publicado: (2023)

Preclinical and Clinical Evaluation of Magnetic-Activated Cell Separation Technology for CTC Isolation in Breast Cancer
por: Lozar, Taja, et al.
Publicado: (2020)

Association of Circulating Tumor Cells, Megakaryocytes and a High Immune-Inflammatory Environment in Metastatic Breast Cancer
por: Grašič Kuhar, Cvetka, et al.
Publicado: (2023)

The Possible Role of Anti- and Protumor-Infiltrating Lymphocytes in Pathologic Complete Response in Early Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy
por: Geršak, Klara, et al.
Publicado: (2023)

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
por: Marinko, Tanja, et al.
Publicado: (2014)

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial
por: Thallinger, Christiane, et al.
Publicado: (2016)

Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Adjuvant trastuzumab: progress, controversies, and the steps ahead
por: Joy, A.A., et al.
Publicado: (2006)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
por: Xu, Qiaoping, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer
por: Aboutorabi, Ali, et al.
Publicado: (2015)

Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapy
por: Soba, Erika, et al.
Publicado: (2015)

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study
por: Campiglio, M., et al.
Publicado: (2013)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
por: Chung, Caroline, et al.
Publicado: (2009)

Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango!
por: Verma, Sunil
Publicado: (2008)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
por: Sardesai, Sagar, et al.
Publicado: (2020)

Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study
por: Blondeaux, Eva, et al.
Publicado: (2020)

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
por: Cataldo, Alessandra, et al.
Publicado: (2018)

Clinical application of the 21-gene oncotype recurrence score in an older cohort: A single center experience
por: Chiru, E.D., et al.
Publicado: (2023)

Adjuvant radiochemotherapy in locally advanced gastric cancer: from evidence to daily clinical practice in a single institution
por: González-Domingo, Manuel, et al.
Publicado: (2020)

Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
por: Shrivastva, Sarita, et al.
Publicado: (2023)

Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe: An initiative of the Central European Cooperative Oncology Group (CECOG)
por: Thallinger, Christiane, et al.
Publicado: (2022)

Trends in Population-based Cancer Survival in Slovenia
por: Zadnik, Vesna, et al.
Publicado: (2021)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
por: Hajjar, Ali, et al.
Publicado: (2019)

Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer
por: Hingmire, Sachin S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b1tvq4253no3i108nchgmurlcc